Author(s):
R. Sunitha, S. Madhavi Latha, M. Pavani, D. Durga Siva Prasad, Shaik Inthiyaz
Email(s):
raminenisunitha@gmail.com
DOI:
10.52711/2231-5691.2025.00032 
Address:
R. Sunitha1*, S. Madhavi Latha2, M. Pavani1, D. Durga Siva Prasad1, Shaik Inthiyaz1
1A M Reddy Memorial College of Pharmacy, Petlurivaripalem, Narasaraopet, A.P.
2Aditya College of Pharmacy, Surampalem, East Godavari (DT), A.P.
*Corresponding Author
Published In:
Volume - 15,
Issue - 2,
Year - 2025
ABSTRACT:
Colorectal cancer (CRC) is the3rd most prevalent cancer, impacting 1 out of 25 women and 1 out of 23 men. CRC is the 2nd leading grounds of cancer-related deaths globally, responsible for more than 608,000 fatalities, which represents 8% of all cancer-related deaths. Various factors, such as age, family history, gender, geography, and personal history, contribute to the development and progression of colorectal cancer. Molecular pathological epidemiology studies can aid in precision medicine and biomarker research by identifying these risk factors. Currently, surgery and chemotherapy are the primary clinical treatments for colorectal cancer. However, the search for new and more effective medications is essential due to the increasing prevalence of adverse effects and drug resistance. Natural compounds have shown promising anti-CRC properties in numerous studies, suggesting their potential as alternative chemotherapeutic agents for colorectal cancer treatment. This review compiles natural products with anti-CRC properties from various sources.
Cite this article:
R. Sunitha, S. Madhavi Latha, M. Pavani, D. Durga Siva Prasad, Shaik Inthiyaz. Medicinal Herbs for Treating Colorectal Cancer – A Comprehensive Review. Asian Journal of Pharmaceutical Research. 2025; 15(2):197-1. doi: 10.52711/2231-5691.2025.00032
Cite(Electronic):
R. Sunitha, S. Madhavi Latha, M. Pavani, D. Durga Siva Prasad, Shaik Inthiyaz. Medicinal Herbs for Treating Colorectal Cancer – A Comprehensive Review. Asian Journal of Pharmaceutical Research. 2025; 15(2):197-1. doi: 10.52711/2231-5691.2025.00032 Available on: https://asianjpr.com/AbstractView.aspx?PID=2025-15-2-17
REFERENCE:
1. Hossain MS, et al., Colorectal Cancer: A Review of Carcinogenesis, Global Epidemiology, Current Challenges, Risk Factors, Preventive and Treatment Strategies. Cancers (Basel). 2022 Mar 29; 14(7):1732. doi: 10.3390/cancers14071732.
2. Sawicki T, et al., A Review of Colorectal Cancer in Terms of Epidemiology, Risk Factors, Development, Symptoms and Diagnosis. Cancers (Basel). 2021 Apr 22; 13(9):2025. doi: 10.3390/cancers13092025.
3. Ma L, Wang Q, et al., The genome and transcriptome analysis of snake gourd provide insights into its evolution and fruit development and ripening. Hortic Res. 2020 Dec 1; 7(1):199. doi: 10.1038/s41438-020-00423-9.
4. Dandawate P, et al., Cucurbitacin B and I inhibits colon cancer growth by targeting the Notch signaling pathway. Sci Rep. 2020 Jan 28; 10(1):1290. doi: 10.1038/s41598-020-57940-9.
5. Chen L, et al., Efficient Production of a Bioactive Bevacizumab Monoclonal Antibody Using the 2A Self-cleavage Peptide in Transgenic Rice Callus. Front Plant Sci. 2016 Aug 9; 7:1156. doi: 10.3389/fpls.2016.01156.
6. Rosen LS, et al., Bevacizumab in Colorectal Cancer: Current Role in Treatment and the Potential of Biosimilars. Target Oncol. 2017 Oct; 12(5):599-610. doi: 10.1007/s11523-017-0518-1.
7. Jaganathan SK, et al., Chemopreventive effect of apple and berry fruits against colon cancer. World J Gastroenterol. 2014 Dec 7; 20(45):17029-36. doi: 10.3748/wjg.v20.i45.17029.
8. Ahmad Najib et al., Utilizing the Pyrx Program to Conduct in Silico Screening of Polyphenol Compounds as Potential Inhibitors of the Epidermal Growth Factor Receptor (EGFR) in Mango Plants (Mangifera Indica) Trop J Nat Prod Res, October 2023; 7(10):4284-4288.
9. Wu B, et al., RAS testing and cetuximab treatment for metastatic colorectal cancer: a cost-effectiveness analysis in a setting with limited health resources. Oncotarget. 2017 Apr 11; 8(41):71164-71172. doi: 10.18632/oncotarget.17029.
10. Ameli H, Alizadeh N. Targeted delivery of capecitabine to colon cancer cells using nano polymeric micelles based on beta cyclodextrin. RSC Adv. 2022 Feb 8; 12(8):4681-4691. doi: 10.1039/d1ra07791k.
11. Singh CK, et al., Resveratrol, in its natural combination in whole grape, for health promotion and disease management. Ann N Y Acad Sci. 2015 Aug; 1348(1):150-60. doi: 10.1111/nyas.12798.
12. Wada H, et al., Resveratrol inhibits development of colorectal adenoma via suppression of LEF1; comprehensive analysis with connectivity map. Cancer Sci. 2022 Dec; 113(12):4374-4384. doi: 10.1111/cas.15576.
13. Sarvizadeh M, et al., Allicin and Digestive System Cancers: From Chemical Structure to Its Therapeutic Opportunities. Front Oncol. 2021 Apr 27; 11:650256. doi: 10.3389/fonc.2021.650256.
14. Song Y, et al., Effectiveness of bevacizumab in the treatment of metastatic colorectal cancer: a systematic review and meta-analysis. BMC Gastroenterol. 2024 Feb 1; 24(1):58. doi: 10.1186/s12876-024-03134-w.
15. Zhang H, et al., Rhein Suppresses Colorectal Cancer Cell Growth by Inhibiting the mTOR Pathway In Vitro and In Vivo. Cancers (Basel). 2021 Apr 30; 13(9):2176. doi: 10.3390/cancers13092176.
16. Chen CP, Ke TW, et al., Ramucirumab in the second-line treatment of metastatic colorectal cancer: a narrative review of literature from clinical trials. Transl Cancer Res. 2020 Sep; 9(9):5645-5654. doi: 10.21037/tcr-20-608.
17. Fusco MJ, et al., FDA Approval Summary: Fruquintinib for the Treatment of Refractory Metastatic Colorectal Cancer. Clin Cancer Res. 2024 Aug 1; 30(15): 3100-3104. doi: 10.1158/1078-0432.CCR-24-0281.
18. Casak SJ, et al., FDA Approval Summary: Tucatinib with Trastuzumab for Advanced Unresectable or Metastatic, Chemotherapy Refractory, HER2-Positive RAS Wild-Type Colorectal Cancer. Clin Cancer Res. 2023 Nov 1; 29(21):4326-4330. doi: 10.1158/1078-0432.CCR-23-1041.
19. Tay RY, et al., Treatment of metastatic colorectal cancer: focus on panitumumab. Cancer Manag Res. 2015 Jun 24; 7:189-98. doi: 10.2147/CMAR.S71821.
20. Ameli H, Alizadeh N. Targeted delivery of capecitabine to colon cancer cells using nano polymeric micelles based on beta cyclodextrin. RSC Adv. 2022 Feb 8; 12(8):4681-4691. doi: 10.1039/d1ra07791k.
21. Hirsch BR, Zafar SY. Capecitabine in the management of colorectal cancer. Cancer Manag Res. 2011; 3:79-89. doi: 10.2147/CMR.S11250.
22. Comella P, Casaretti R, Sandomenico C, Avallone A, Franco L. Role of oxaliplatin in the treatment of colorectal cancer. Ther Clin Risk Manag. 2009 Feb; 5(1):229-38. doi: 10.2147/tcrm.s3583.
23. Pavlidis ET, Pavlidis TE. Role of bevacizumab in colorectal cancer growth and its adverse effects: a review. World J Gastroenterol. 2013 Aug 21; 19(31):5051-60. doi: 10.3748/wjg.v19.i31.5051.
24. Pagano E, et al., Palmitoyl ethanolamide Reduces Colon Cancer Cell Proliferation and Migration, Influences Tumor Cell Cycle and Exerts In Vivo Chemopreventive Effects. Cancers (Basel). 2021 Apr 16; 13(8):1923. doi: 10.3390/cancers13081923.
25. Tummala S, et al., Formulation and characterization of 5-Fluorouracil enteric coated nanoparticles for sustained and localized release in treating colorectal cancer. Saudi Pharm J. 2015 Jul; 23(3):308-14. doi: 10.1016/j.jsps.2014.11.010.
26. Park D, Lee JH, Yoon SP. Anti-cancer effects of fenbendazole on 5-fluorouracil-resistant colorectal cancer cells. Korean J Physiol Pharmacol. 2022 Sep 1; 26(5):377-387. doi: 10.4196/kjpp.2022.26.5.377.
27. Song HM, et al., Vitex rotundifolia Fruit Suppresses the Proliferation of Human Colorectal Cancer Cells through Down-regulation of Cyclin D1 and CDK4 via Proteasomal-Dependent Degradation and Transcriptional Inhibition. Am J Chin Med. 2018; 46(1):191-207. doi: 10.1142/S0192415X18500118.
28. Comella P, et al., Role of oxaliplatin in the treatment of colorectal cancer. Ther Clin Risk Manag. 2009 Feb; 5(1):229-38. doi: 10.2147/tcrm.s3583.
29. Hao Q, Wang M, Sun NX, Zhu C, Lin YM, Li C, Liu F, Zhu WW. Sulforaphane suppresses carcinogenesis of colorectal cancer through the ERK/Nrf2 UDP glucuronosyltransferase 1A metabolic axis activation. Oncol Rep. 2020 Apr; 43(4):1067-1080. doi: 10.3892/or.2020.7495.
30. Hao Q, et al., Sulforaphane suppresses carcinogenesis of colorectal cancer through the ERK/Nrf2 UDP glucuronosyltransferase 1A metabolic axis activation. Oncol Rep. 2020 Apr; 43(4):1067-1080. doi: 10.3892/or.2020.7495.
31. González-Vallinas M, et al., Antitumor effect of 5-fluorouracil is enhanced by rosemary extract in both drug sensitive and resistant colon cancer cells. Pharmacol Res. 2013 Jun; 72:61-8. doi: 10.1016/j.phrs.2013.03.010.
32. Wu Z, et al., Review of ferroptosis in colorectal cancer: Friends or foes? World J Gastroenterol. 2023 Jan 21; 29(3):469-486. doi: 10.3748/wjg.v29.i3.469.
33. Feng H, et al., Formulation and evaluation of irinotecan suppository for rectal administration. Biomol Ther (Seoul). 2014 Jan; 22(1):78-81. doi: 10.4062/biomolther.2013.087.
34. Du T, Han J. Arginine Metabolism and Its Potential in Treatment of Colorectal Cancer. Front Cell Dev Biol. 2021 May 20; 9:658861. doi: 10.3389/fcell.2021.658861.
35. Wu B, et al., RAS testing and cetuximab treatment for metastatic colorectal cancer: a cost-effectiveness analysis in a setting with limited health resources. Oncotarget. 2017 Apr 11; 8(41):71164-71172. doi: 10.18632/oncotarget.17029.
`